PHENYTEK

Post-LOE

extended phenytoin sodium

Viatris (2)

ANDAORALCAPSULE

Approved

Dec 1998

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

PHENYTEK (extended phenytoin sodium) by Viatris (2) is voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained high-frequency neuronal discharges. Approved for tonic-clonic (grand mal), psychomotor (temporal lobe) seizures, prevention and 2 more indications. First approved in 1998.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained high-frequency neuronal discharges.

Indications (5)

tonic-clonic (grand mal)psychomotor (temporal lobe) seizures prevention

Worked on PHENYTEK at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.